Protagonist Therapeutics (PTGX)
Protagonist Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
10.3M
Short interest
settlement 2026-10-15
12.0
Days to cover
+0.5 days vs prior
57.5%
Short share of volume
2026-11-02
1,263
Fails to deliver
settlement 2026-10-06
Thu 5 Nov
Next earnings
estimated date
-$41.4M
Insider flow, 90 days
0 buys, 7 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in PTGX is 10,297,224 shares, up 2,157,030 shares over the last month. Over the last 48 readings it ranged from 3,282,001 shares (31 October 2024) to 10,297,224 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 856K shares a day that is 12.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/ptgx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 10,297,224 | +10.2% | 856,448 | 12.02 |
| 2026-09-30 | 9,345,382 | +14.8% | 813,300 | 11.49 |
| 2026-09-15 | 8,140,194 | +5.5% | 538,023 | 15.13 |
| 2026-08-31 | 7,712,543 | -1.0% | 502,802 | 15.34 |
| 2026-08-14 | 7,791,795 | +3.3% | 474,581 | 16.42 |
| 2026-07-31 | 7,543,109 | -9.0% | 530,739 | 14.21 |
| 2026-07-15 | 8,292,656 | +7.8% | 870,374 | 9.53 |
| 2026-06-30 | 7,691,347 | -0.5% | 1,065,176 | 7.22 |
| 2026-06-15 | 7,728,416 | +4.3% | 666,636 | 11.59 |
| 2026-05-29 | 7,410,849 | +1.6% | 440,776 | 16.81 |
| 2026-05-15 | 7,293,819 | -3.3% | 571,831 | 12.76 |
| 2026-04-30 | 7,540,996 | -10.2% | 634,719 | 11.88 |
| 2026-04-15 | 8,397,278 | -2.7% | 723,038 | 11.61 |
| 2026-03-31 | 8,626,880 | +7.0% | 1,129,332 | 7.64 |
| 2026-03-13 | 8,060,991 | -1.6% | 741,047 | 10.88 |
| 2026-02-27 | 8,192,998 | -3.0% | 497,018 | 16.48 |
| 2026-02-13 | 8,443,732 | +3.8% | 634,572 | 13.31 |
| 2026-01-30 | 8,132,629 | -2.0% | 769,818 | 10.56 |
| 2026-01-15 | 8,297,775 | +13.8% | 948,734 | 8.75 |
| 2025-12-31 | 7,292,034 | +11.5% | 767,016 | 9.51 |
| 2025-12-15 | 6,539,025 | +11.2% | 1,088,905 | 6.01 |
| 2025-11-28 | 5,883,017 | +5.4% | 832,587 | 7.07 |
| 2025-11-14 | 5,582,326 | +2.1% | 954,588 | 5.85 |
| 2025-10-31 | 5,465,729 | -13.4% | 976,387 | 5.60 |
| 2025-10-15 | 6,312,028 | -5.0% | 1,934,974 | 3.26 |
| 2025-09-30 | 6,641,782 | -0.3% | 1,182,307 | 5.62 |
| 2025-09-15 | 6,659,476 | -2.7% | 1,150,280 | 5.79 |
| 2025-08-29 | 6,846,871 | +8.5% | 687,472 | 9.96 |
| 2025-08-15 | 6,310,889 | +9.6% | 632,261 | 9.98 |
| 2025-07-31 | 5,757,412 | -6.9% | 649,343 | 8.87 |
| 2025-07-15 | 6,183,934 | -8.1% | 785,080 | 7.88 |
| 2025-06-30 | 6,731,615 | +13.8% | 1,061,213 | 6.34 |
| 2025-06-13 | 5,913,322 | +13.5% | 1,018,592 | 5.81 |
| 2025-05-30 | 5,209,196 | -1.5% | 687,034 | 7.58 |
| 2025-05-15 | 5,287,293 | -13.6% | 861,666 | 6.14 |
| 2025-04-30 | 6,116,314 | +9.8% | 933,073 | 6.56 |
| 2025-04-15 | 5,568,227 | +18.3% | 1,546,216 | 3.60 |
| 2025-03-31 | 4,706,298 | -8.3% | 1,215,189 | 3.87 |
| 2025-03-14 | 5,129,814 | +5.4% | 2,061,341 | 2.49 |
| 2025-02-28 | 4,865,114 | +15.3% | 848,244 | 5.74 |
| 2025-02-14 | 4,221,220 | +11.3% | 551,115 | 7.66 |
| 2025-01-31 | 3,793,117 | +3.3% | 496,389 | 7.64 |
| 2025-01-15 | 3,670,399 | -3.4% | 611,813 | 6.00 |
| 2024-12-31 | 3,798,682 | +5.3% | 690,804 | 5.50 |
| 2024-12-13 | 3,608,116 | +6.1% | 608,450 | 5.93 |
| 2024-11-29 | 3,399,522 | +3.0% | 1,070,718 | 3.17 |
| 2024-11-15 | 3,301,009 | +0.6% | 670,290 | 4.92 |
| 2024-10-31 | 3,282,001 | +9.3% | 404,257 | 8.12 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of PTGX volume is 57.5%, down 20.3 points over the last five sessions. Over the last 30 readings it ranged from 37.1% (20 October 2026) to 87.9% (7 October 2026). The latest reading is 12.3 points below the 30-session average of 69.8%, on 125K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 72K | 125K | 57.5% | 16 |
| 2026-10-30 | 60K | 104K | 57.8% | 400 |
| 2026-10-29 | 70K | 112K | 62.4% | 1,017 |
| 2026-10-28 | 57K | 92K | 62.0% | 200 |
| 2026-10-27 | 103K | 185K | 55.4% | 0 |
| 2026-10-26 | 121K | 156K | 77.8% | 55 |
| 2026-10-23 | 89K | 138K | 64.5% | 352 |
| 2026-10-22 | 104K | 134K | 77.2% | 920 |
| 2026-10-21 | 158K | 247K | 63.9% | 375 |
| 2026-10-20 | 102K | 274K | 37.1% | 23 |
| 2026-10-19 | 151K | 233K | 64.6% | 12 |
| 2026-10-16 | 278K | 373K | 74.7% | 0 |
| 2026-10-15 | 197K | 261K | 75.7% | 667 |
| 2026-10-14 | 150K | 192K | 78.3% | 0 |
| 2026-10-13 | 313K | 415K | 75.3% | 20 |
| 2026-10-12 | 303K | 394K | 77.0% | 1,078 |
| 2026-10-09 | 312K | 388K | 80.3% | 1,440 |
| 2026-10-08 | 420K | 504K | 83.3% | 0 |
| 2026-10-07 | 419K | 476K | 87.9% | 252 |
| 2026-10-06 | 154K | 274K | 56.1% | 0 |
| 2026-10-05 | 238K | 276K | 86.2% | 202 |
| 2026-10-02 | 183K | 283K | 64.8% | 0 |
| 2026-10-01 | 208K | 417K | 49.9% | 0 |
| 2026-09-30 | 206K | 236K | 87.3% | 997 |
| 2026-09-29 | 150K | 201K | 74.6% | 900 |
| 2026-09-28 | 334K | 383K | 87.3% | 0 |
| 2026-09-25 | 311K | 403K | 77.3% | 0 |
| 2026-09-24 | 228K | 368K | 61.9% | 161 |
| 2026-09-23 | 118K | 187K | 63.0% | 0 |
| 2026-09-22 | 213K | 290K | 73.6% | 12,242 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 6 October 2026, the fails-to-deliver balance in PTGX is 1,263 shares, down 52,355 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (4 August 2026) to 56,454 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-06 | 1,263 | $140.63 | $178K |
| 2026-10-01 | 53,618 | $140.89 | $7.6M |
| 2026-09-15 | 3,133 | $147.78 | $463K |
| 2026-09-09 | 28,995 | $145.94 | $4.2M |
| 2026-09-03 | 47,443 | $146.08 | $6.9M |
| 2026-09-02 | 1,629 | $146.49 | $239K |
| 2026-08-26 | 2,090 | $150.59 | $315K |
| 2026-08-19 | 2,100 | $157.34 | $330K |
| 2026-08-06 | 94 | $137.32 | $13K |
| 2026-08-04 | 2 | $132.28 | $265 |
| 2026-07-30 | 910 | $133.00 | $121K |
| 2026-07-24 | 209 | $135.43 | $28K |
| 2026-07-23 | 222 | $135.44 | $30K |
| 2026-07-22 | 1,244 | $138.31 | $172K |
| 2026-07-20 | 33 | $140.91 | $5K |
| 2026-07-17 | 375 | $132.02 | $50K |
| 2026-07-16 | 9 | $135.46 | $1K |
| 2026-07-14 | 133 | $129.89 | $17K |
| 2026-06-30 | 223 | $121.63 | $27K |
| 2026-06-29 | 56,454 | $121.88 | $6.9M |
| 2026-06-25 | 3,535 | $122.15 | $432K |
| 2026-06-24 | 2,269 | $118.96 | $270K |
| 2026-06-23 | 19 | $115.03 | $2K |
| 2026-06-22 | 9 | $112.86 | $1K |
| 2026-06-15 | 430 | $109.78 | $47K |
| 2026-06-12 | 4 | $109.79 | $439 |
| 2026-06-11 | 30,000 | $105.77 | $3.2M |
| 2026-06-09 | 21 | $98.03 | $2K |
| 2026-06-05 | 48 | $102.79 | $5K |
| 2026-06-04 | 325 | $95.41 | $31K |
Insider trades
SEC Form 4, newest first. JSONInsiders at PTGX reported 7 open-market sells worth $41.4M in the last 90 days and no open-market buys. Latest filing: Ali Asif (Chief Financial Officer) on 2026-09-30.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Ali Asif | Chief Financial Officer | Sell | 46K | $141.78 | $6.5M | 59K |
| 2026-09-30 | Ali Asif | Chief Financial Officer | Sell | 13K | $141.77 | $1.8M | 105K |
| 2026-09-30 | Ali Asif | Chief Financial Officer | Exercise or conversion | 5K | $12.17 | $65K | 118K |
| 2026-09-30 | Ali Asif | Chief Financial Officer | Exercise or conversion | 16K | $19.19 | $300K | 112K |
| 2026-09-30 | Ali Asif | Chief Financial Officer | Exercise or conversion | 28K | $23.42 | $666K | 97K |
| 2026-09-30 | Ali Asif | Chief Financial Officer | Exercise or conversion | 9K | $38.98 | $360K | 68K |
| 2026-09-10 | PATEL DINESH V PH D | President and CEO | Sell | 7K | $144.10 | $1.0M | 523K |
| 2026-09-10 | PATEL DINESH V PH D | President and CEO | Exercise or conversion | 7K | $21.58 | $157K | 530K |
| 2026-09-09 | PATEL DINESH V PH D | President and CEO | Sell | 64K | $146.18 | $9.3M | 523K |
| 2026-09-09 | PATEL DINESH V PH D | President and CEO | Exercise or conversion | 64K | $21.58 | $1.4M | 587K |
| 2026-09-08 | PATEL DINESH V PH D | President and CEO | Sell | 54K | $145.87 | $7.9M | 523K |
| 2026-09-08 | PATEL DINESH V PH D | President and CEO | Exercise or conversion | 54K | $21.58 | $1.2M | 577K |
| 2026-09-03 | PATEL DINESH V PH D | President and CEO | Gift | 510 | $0.00 | $0 | 523K |
| 2026-08-11 | PATEL DINESH V PH D | President and CEO | Sell | 34K | $148.52 | $5.1M | 523K |
| 2026-08-11 | PATEL DINESH V PH D | President and CEO | Exercise or conversion | 34K | $21.58 | $739K | 558K |
| 2026-08-10 | PATEL DINESH V PH D | President and CEO | Sell | 66K | $149.11 | $9.8M | 523K |
| 2026-08-10 | PATEL DINESH V PH D | President and CEO | Exercise or conversion | 66K | $21.58 | $1.4M | 589K |
| 2026-06-23 | Waddill William D. | Director | Sell | 9K | $117.94 | $1.1M | 8K |
| 2026-06-23 | Waddill William D. | Director | Exercise or conversion | 9K | $16.54 | $149K | 17K |
| 2026-06-10 | Waddill William D. | Director | Sell | 9K | $107.68 | $969K | 8K |
| 2026-06-10 | Waddill William D. | Director | Exercise or conversion | 6K | $16.54 | $99K | 17K |
| 2026-06-10 | Waddill William D. | Director | Exercise or conversion | 3K | $11.80 | $35K | 11K |
| 2026-05-29 | Waddill William D. | Director | Sell | 9K | $99.64 | $897K | 8K |
| 2026-05-29 | Waddill William D. | Director | Exercise or conversion | 9K | $11.80 | $106K | 17K |
| 2026-05-12 | PATEL DINESH V PH D | President and CEO | Sell | 75K | $100.12 | $7.5M | 523K |
| 2026-05-12 | PATEL DINESH V PH D | President and CEO | Exercise or conversion | 75K | $21.58 | $1.6M | 598K |
| 2026-05-08 | Giraudo Bryan | Director | Sell | 5K | $100.00 | $513K | 13K |
| 2026-05-08 | Giraudo Bryan | Director | Sell | 6K | $100.00 | $600K | 0 |
| 2026-05-07 | Giraudo Bryan | Director | Sell | 12K | $100.07 | $1.2M | 6K |
| 2026-05-07 | Giraudo Bryan | Director | Sell | 36K | $100.14 | $3.6M | 28K |
| 2026-05-07 | Giraudo Bryan | Director | Exercise or conversion | 12K | $6.98 | $84K | 44K |
| 2026-05-07 | Giraudo Bryan | Director | Exercise or conversion | 24K | $6.45 | $155K | 32K |
| 2026-04-23 | PATEL DINESH V PH D | President and CEO | Gift | 1K | $0.00 | $0 | 523K |
| 2026-04-20 | Ali Asif | Chief Financial Officer | Sell | 2K | $105.47 | $185K | 59K |
| 2026-03-26 | SELICK HAROLD E | Director | Sell | 24K | $105.00 | $2.5M | 61K |
| 2026-03-26 | SELICK HAROLD E | Director | Exercise or conversion | 24K | $12.88 | $309K | 85K |
| 2026-03-26 | MOLINA ARTURO MD | Chief Medical Officer | Sell | 15K | $104.79 | $1.6M | 84K |
| 2026-03-26 | MOLINA ARTURO MD | Chief Medical Officer | Exercise or conversion | 15K | $8.04 | $121K | 99K |
| 2026-03-26 | Ali Asif | Chief Financial Officer | Sell | 25K | $104.24 | $2.6M | 61K |
| 2026-03-26 | Ali Asif | Chief Financial Officer | Exercise or conversion | 5K | $12.17 | $64K | 86K |
| 2026-03-26 | Ali Asif | Chief Financial Officer | Exercise or conversion | 20K | $19.19 | $374K | 80K |
| 2026-03-25 | PATEL DINESH V PH D | President and CEO | Sell | 55K | $101.00 | $5.5M | 525K |
| 2026-03-25 | PATEL DINESH V PH D | President and CEO | Exercise or conversion | 55K | $8.58 | $469K | 580K |
| 2026-03-24 | PATEL DINESH V PH D | President and CEO | Sell | 59 | $101.00 | $6K | 525K |
| 2026-03-24 | PATEL DINESH V PH D | President and CEO | Exercise or conversion | 59 | $8.58 | $506 | 525K |
| 2026-03-23 | PATEL DINESH V PH D | President and CEO | Gift | 50K | $0.00 | $0 | 525K |
| 2026-02-17 | Williams Lewis T | Director | Sell | 18K | $82.42 | $1.5M | 8K |
| 2026-02-17 | Williams Lewis T | Director | Exercise or conversion | 18K | $10.84 | $195K | 26K |
| 2026-02-06 | Waddill William D. | Director | Sell | 20K | $83.68 | $1.7M | 8K |
| 2026-02-06 | Waddill William D. | Director | Exercise or conversion | 20K | $8.31 | $166K | 28K |
| 2026-01-27 | PATEL DINESH V PH D | President and CEO | Sell | 4K | $83.19 | $338K | 575K |
| 2026-01-27 | PATEL DINESH V PH D | President and CEO | Exercise or conversion | 4K | $21.58 | $88K | 579K |
| 2026-01-27 | MOLINA ARTURO MD | Chief Medical Officer | Sell | 5K | $82.00 | $410K | 84K |
| 2026-01-27 | MOLINA ARTURO MD | Chief Medical Officer | Exercise or conversion | 5K | $8.04 | $40K | 89K |
| 2026-01-27 | Ali Asif | Chief Financial Officer | Sell | 18K | $83.14 | $1.5M | 60K |
| 2026-01-27 | Ali Asif | Chief Financial Officer | Sell | 28K | $83.13 | $2.3M | 79K |
| 2026-01-27 | Ali Asif | Chief Financial Officer | Exercise or conversion | 12K | $12.17 | $146K | 107K |
| 2026-01-27 | Ali Asif | Chief Financial Officer | Exercise or conversion | 16K | $19.19 | $307K | 95K |
| 2026-01-26 | PATEL DINESH V PH D | President and CEO | Sell | 14K | $84.05 | $1.2M | 575K |
| 2026-01-26 | PATEL DINESH V PH D | President and CEO | Exercise or conversion | 14K | $21.58 | $307K | 589K |
| 2026-01-26 | PATEL DINESH V PH D | President and CEO | Sell | 11K | $84.00 | $898K | 575K |
| 2026-01-26 | PATEL DINESH V PH D | President and CEO | Exercise or conversion | 11K | $4.21 | $45K | 585K |
| 2026-01-26 | MOLINA ARTURO MD | Chief Medical Officer | Sell | 5K | $82.28 | $411K | 84K |
| 2026-01-26 | MOLINA ARTURO MD | Chief Medical Officer | Exercise or conversion | 5K | $8.04 | $40K | 89K |
| 2026-01-23 | PATEL DINESH V PH D | President and CEO | Sell | 19K | $84.59 | $1.6M | 575K |
| 2026-01-23 | PATEL DINESH V PH D | President and CEO | Exercise or conversion | 19K | $4.21 | $81K | 594K |
| 2026-01-23 | PATEL DINESH V PH D | President and CEO | Gift | 6K | $0.00 | $0 | 575K |
| 2026-01-23 | MOLINA ARTURO MD | Chief Medical Officer | Sell | 13K | $82.42 | $1.1M | 84K |
| 2026-01-20 | PATEL DINESH V PH D | President and CEO | Sell | 34K | $82.48 | $2.8M | 581K |
| 2026-01-20 | MOLINA ARTURO MD | Chief Medical Officer | Sell | 10K | $82.48 | $785K | 97K |
| 2026-01-20 | Ali Asif | Chief Financial Officer | Sell | 9K | $82.48 | $708K | 78K |
| 2026-01-09 | SELICK HAROLD E | Director | Exercise or conversion | 14K | $4.21 | $60K | 61K |
| 2026-01-02 | SELICK HAROLD E | Director | Grant | 3K | $0.00 | $0 | 47K |
| 2026-01-02 | Waddill William D. | Director | Grant | 3K | $0.00 | $0 | 8K |
| 2026-01-02 | Williams Lewis T | Director | Grant | 3K | $0.00 | $0 | 8K |
| 2026-01-02 | PATEL DINESH V PH D | President and CEO | Grant | 95K | $0.00 | $0 | 615K |
| 2026-01-02 | O'Dowd Sarah A | Director | Grant | 3K | $0.00 | $0 | 8K |
| 2026-01-02 | MOLINA ARTURO MD | Chief Medical Officer | Grant | 26K | $0.00 | $0 | 107K |
| 2026-01-02 | Giraudo Bryan | Director | Grant | 3K | $0.00 | $0 | 18K |
| 2026-01-02 | Ali Asif | Chief Financial Officer | Grant | 26K | $0.00 | $0 | 87K |
| 2025-11-21 | PATEL DINESH V PH D | President and CEO | Gift | 440 | $0.00 | $0 | 520K |
| 2025-11-17 | MOLINA ARTURO MD | Chief Medical Officer | Sell | 3K | $84.77 | $230K | 81K |
| 2025-10-10 | Waddill William D. | Director | Sell | 8K | $87.81 | $702K | 5K |
| 2025-10-10 | Waddill William D. | Director | Sell | 4K | $69.25 | $277K | 13K |
| 2025-10-10 | Waddill William D. | Director | Exercise or conversion | 12K | $6.98 | $84K | 17K |
| 2025-09-22 | Waddill William D. | Director | Sell | 4K | $64.25 | $257K | 5K |
| 2025-09-16 | PATEL DINESH V PH D | President and CEO | Gift | 620 | $0.00 | $0 | 520K |
| 2025-08-27 | Waddill William D. | Director | Sell | 4K | $59.25 | $237K | 9K |
| 2025-07-25 | PATEL DINESH V PH D | President and CEO | Sell | 10K | $54.78 | $571K | 521K |
| 2025-07-23 | PATEL DINESH V PH D | President and CEO | Sell | 18K | $54.79 | $960K | 531K |
| 2025-07-22 | PATEL DINESH V PH D | President and CEO | Sell | 22K | $55.05 | $1.2M | 549K |
| 2025-07-21 | PATEL DINESH V PH D | President and CEO | Sell | 13K | $54.86 | $705K | 571K |
| 2025-07-21 | PATEL DINESH V PH D | President and CEO | Grant | 25K | $0.00 | $0 | 583K |
| 2025-07-16 | PATEL DINESH V PH D | President and CEO | Gift | 5K | $0.00 | $0 | 558K |
| 2025-06-16 | PATEL DINESH V PH D | President and CEO | Gift | 685 | $0.00 | $0 | 563K |
| 2025-06-13 | PATEL DINESH V PH D | President and CEO | Gift | 670 | $0.00 | $0 | 564K |
| 2025-06-10 | MOLINA ARTURO MD | Chief Medical Officer | Sell | 10K | $57.03 | $570K | 84K |
| 2025-06-10 | MOLINA ARTURO MD | Chief Medical Officer | Exercise or conversion | 10K | $8.04 | $80K | 94K |
| 2025-06-09 | MOLINA ARTURO MD | Chief Medical Officer | Exercise or conversion | 10K | $8.04 | $80K | 94K |
| 2025-06-09 | MOLINA ARTURO MD | Chief Medical Officer | Sell | 10K | $55.51 | $555K | 84K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON21 Form 144 notices on file for PTGX worth $46.1M at the prices reported; 1 in the last 90 days worth $8.3M. Latest: ASIF ALI filed on 2026-09-30 to sell 58,629 shares ($8.3M) from 2026-09-30.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-30 | ASIF ALIOfficer | 59K | $8.3M | 0.091% | 2026-09-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-23 | WILLIAM WADDILLDirector | 9K | $1.0M | 0.014% | 2026-06-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-10 | WILLIAM WADDILLDirector | 9K | $953K | 0.014% | 2026-06-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-29 | WILLIAM WADDILLDirector | 9K | $904K | 0.014% | 2026-05-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-08 | BRYAN M & COURTNEY L GIRAUDO RTDirector | 11K | $1.1M | 0.017% | 2026-05-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-07 | BRYAN GIRAUDODirector | 36K | $3.6M | 0.056% | 2026-05-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-07 | BRYAN M & COURTNEY L GIRAUDO RTDirector | 12K | $1.2M | 0.019% | 2026-05-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-21 | Asif AliOfficer | 2K | $185K | 0.003% | 2026-04-20 | Morgan Stanley Smith Barney Operations Department |
| 2026-03-24 | Dinesh PatelCEO | 55K | $5.4M | 0.086% | 2026-03-24 | J.P. Morgan Securities LLC |
| 2026-02-17 | LEWIS T WILLIAMSDirector | 18K | $1.5M | 0.029% | 2026-02-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-06 | WILLIAM D WADDILLDirector | 20K | $1.7M | 0.032% | 2026-02-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-27 | ARTURO MOLINAOfficer | 5K | $410K | 0.008% | 2026-01-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-27 | ASIF ALIOfficer | 46K | $3.8M | 0.074% | 2026-01-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-26 | ARTURO MOLINAOfficer | 5K | $411K | 0.008% | 2026-01-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-23 | Dinesh PatelCEO | 108K | $9.2M | 0.173% | 2026-01-23 | J.P. Morgan Securities LLC |
| 2026-01-23 | ARTURO MOLINAOfficer | 13K | $1.1M | 0.021% | 2026-01-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-21 | DINESH V PATEL PH DOfficer, Director | 34K | $2.8M | 0.055% | 2026-01-20 | Morgan Stanley Smith Barney Operations Department |
| 2026-01-21 | ARTURO MOLINA MDOfficer | 10K | $785K | 0.015% | 2026-01-20 | Morgan Stanley Smith Barney Operations Department |
| 2026-01-21 | Asif AliOfficer | 9K | $708K | 0.014% | 2026-01-20 | Morgan Stanley Smith Barney Operations Department |
| 2025-10-10 | WILLIAM WADDILLDirector | 12K | $804K | 0.019% | 2025-10-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-22 | WILLIAM WADDILLDirector | 4K | $249K | 0.006% | 2025-09-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first, 50 of 55 shown. JSON25 holders report 5% or more of PTGX in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 15.2% of the class (9,834,146 shares), filed 2026-10-27 for an event on 2026-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 8 | BlackRock, Inc.parent holding company | 9.8M | 15.2% | 2026-09-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon Capital Management, L.L.C.investment adviser, other entity | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Wehrly, Mark C.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Dreyfuss, Philip D.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Dunn Hannah E.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Gehani, Varun N.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Giauque, Nicolasparent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Husen, Avner A.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Kim, David T.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Linn, Michael G.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Luo Patrick (Cheng)parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Roberts, Jr., Thomas G.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Saito Edric C.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Short Daniel S.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Spokes, Andrew J. M.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Warren, John R.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Dapice Joshua J.parent holding company, individual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon Capital Institutional Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon Capital Institutional Partners II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon Capital Institutional Partners III, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Four Crossings Institutional Partners V, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon Capital Offshore Investors II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon Capital (AM) Investors, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon Capital F5 Master I, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon Healthcare Partners Master, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon Partners, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon Institutional (GP) V, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon F5 (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon Healthcare Partners (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 9 | Farallon Capital Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 3.3M | 5.2% | 2026-06-30 |
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 3.3M | 5.1% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Portfolio Managementinvestment adviser | 3.5M | 5.5% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 5 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 6 | Roderick Wongparent holding company, individual | 5.1M | 8.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 6 | RTW Investments, LPinvestment adviser, partnership | 5.1M | 8.1% | 2025-12-31 |
| 2026-02-10 | 13G | Wellington Investment Advisors Holdings LLPparent holding company | 3.2M | 5.1% | 2025-12-31 |
| 2026-02-10 | 13G | Wellington Group Holdings LLPparent holding company | 3.2M | 5.1% | 2025-12-31 |
| 2026-02-10 | 13G | Wellington Management Group LLPparent holding company | 3.2M | 5.1% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 8 | Fried, Richard Bindividual | 0 | 0.0% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 8 | Patel, Rajiv A.individual | 0 | 0.0% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 8 | Seybold, Williamindividual | 0 | 0.0% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 1 | Deep Track Capital, LPinvestment adviser, other entity | 1.7M | 2.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Deep Track Biotechnology Master Fund, Ltd.corporation | 1.7M | 2.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | David Kroinparent holding company, individual | 1.7M | 2.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | LAMPERT MARK Nindividual | 2.6M | 4.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF INC/ILcorporation | 2.6M | 4.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF PARTNERS L P/ILinvestment adviser, partnership | 2.6M | 4.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BVF GP HOLDINGS LLCother entity | 2.4M | 3.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 1.3M | 2.1% | 2025-09-30 |
13F holders
Tracked managers holding PTGX at their latest 13F. JSON4 of the 30 tracked managers held PTGX at their latest 13F, $49.3M in total at quarter-end prices. Duquesne Family Office is the largest at $25.6M (0.5% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Duquesne Family Office | 2026-06-30 | 209K | $25.6M | 0.49% | +49K |
| Fisher Asset Management | 2026-06-30 | 171K | $20.9M | 0.01% | -3K |
| AQR Capital Management | 2026-06-30 | 13K | $1.6M | 0.00% | +1K |
| Bridgewater Associates | 2026-06-30 | 9K | $1.1M | 0.00% | +4K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Protagonist Therapeutics reported revenue of $213.5M, up 3749.2% from the same quarter a year earlier, and net income of $162.8M (2.29 diluted EPS). In FY 2025 it generated $57.7M of operating cash flow.
- Cash
- $420.1M
- Equity
- $841.5M
- Total assets
- $885.5M
- Shares outstanding
- 64,708,285
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $213.5M | $162.8M | 76.3% | 2.29 |
| Q1 FY 2026 | 2026-03-31 | n/a | $3.8M | n/a | 0.05 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$44.4M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$39.3M | n/a | -0.62 |
| Q2 FY 2025 | 2025-06-30 | $5.5M | -$34.8M | -627.0% | -0.55 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$11.7M | n/a | -0.19 |
| Q4 FY 2024derived | 2024-12-31 | n/a | $131.7M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$33.2M | n/a | -0.54 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$130.1M | $57.7M | $1.6M | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | $275.2M | $184.2M | $1.4M | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$79.0M | -$70.2M | $609K | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$127.4M | -$108.1M | $795K | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$125.6M | -$107.9M | $1.1M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Protagonist Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Protagonist Therapeutics (PTGX), SEC CIK 1377121, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-06.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-30.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-30.JSON and CSV
- Company record
- EDGAR filing index for CIK 1377121Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of PTGX is sold short?
10,297,224 shares were held short at the 2026-10-15 settlement, 12.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is PTGX's daily short volume?
On 2026-11-02, 71,634 of the 124,580 PTGX shares reported to FINRA were sold short, 57.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does PTGX have fails to deliver?
The SEC's latest file shows 1,263 PTGX shares failed to deliver at settlement 2026-10-06. Fails are reported per settlement date and published twice a month with a lag.
Are PTGX insiders buying or selling?
Insiders at PTGX reported 7 open-market sells worth $41.4M in the last 90 days and no open-market buys. Latest filing: Ali Asif (Chief Financial Officer) on 2026-09-30.
Have PTGX insiders filed to sell?
21 Form 144 notices on file for PTGX worth $46.1M at the prices reported; 1 in the last 90 days worth $8.3M. Latest: ASIF ALI filed on 2026-09-30 to sell 58,629 shares ($8.3M) from 2026-09-30.
Who owns 5% or more of PTGX?
25 holders report 5% or more of PTGX in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 15.2% of the class (9,834,146 shares), filed 2026-10-27 for an event on 2026-09-30.
What did PTGX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Protagonist Therapeutics reported revenue of $213.5M, up 3749.2% from the same quarter a year earlier, and net income of $162.8M (2.29 diluted EPS). In FY 2025 it generated $57.7M of operating cash flow.
Which tracked 13F managers own PTGX?
4 of the 30 tracked 13F managers held PTGX shares at their latest filing, $49.3M in all. The largest: Stanley Druckenmiller's Duquesne Family Office (209K shares, $25.6M), Ken Fisher's Fisher Asset Management (171K shares, $20.9M), Cliff Asness's AQR Capital Management (13K shares, $1.6M), Ray Dalio's Bridgewater Associates (9K shares, $1.1M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.